These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 3263077)
1. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients. Brenner BG; McCrea EL; Margolese RG Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077 [TBL] [Abstract][Full Text] [Related]
2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856 [TBL] [Abstract][Full Text] [Related]
5. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann GG; Zeuthen J; Claësson MH Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282 [TBL] [Abstract][Full Text] [Related]
6. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells. Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786 [TBL] [Abstract][Full Text] [Related]
7. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
9. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
10. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells. Burns GF; Triglia T; Werkmeister JA J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374 [TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Vujanovic NL; Herberman RB; Hiserodt JC Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411 [TBL] [Abstract][Full Text] [Related]
12. [The effect of sera of breast cancer patients on NK cell activity]. Konjević G; Spuzić I Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436 [TBL] [Abstract][Full Text] [Related]
15. Effects of herpes simplex virus on induced cell-mediated cytotoxicity in neonates and adults. Chin TW; Plaeger-Marshall S; Ank BJ; Pressman SR; Stiehm ER Nat Immun Cell Growth Regul; 1991; 10(5):237-46. PubMed ID: 1661847 [TBL] [Abstract][Full Text] [Related]
16. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
17. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
18. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
19. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood. Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745 [TBL] [Abstract][Full Text] [Related]
20. Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors. Vie H; Bonneville M; Sondermeyer P; Moreau JF; Soulillou JP Immunology; 1986 Mar; 57(3):351-7. PubMed ID: 3082744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]